Related Experiment Video

Updated: Aug 9, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K

L-carnitine attenuated hyperuricemia-associated left ventricular remodeling through ameliorating cardiomyocytic lipid

Yang Yang1,2,3, Cuiting Lin3, Qiang Zheng3

  • 1Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, Guangdong, China.

Frontiers in Pharmacology
|February 23, 2023
PubMed

Insights

High uric acid (HUA) impairs heart cell fatty acid (FA) metabolism, causing cardiac remodeling. L-carnitine (LC) treatment improves FA transport and reduces heart damage, offering a potential therapy for HUA-related cardiovascular disease.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Molecular Biology

Background:

  • Hyperuricemia (HUA) is linked to left ventricular remodeling (LVR) and cardiovascular diseases.
  • Left ventricular remodeling involves cardiomyocyte energy metabolic dysfunction.
  • The impact of HUA on cardiomyocyte fatty acid (FA) metabolism remains largely unknown.

Purpose of the Study:

  • To investigate the effect of HUA on cardiomyocyte FA metabolism.
  • To explore the therapeutic potential of L-carnitine (LC) in HUA-associated cardiac dysfunction.

Main Methods:

  • Utilized a mouse model of HUA.
  • Assessed cardiomyocyte injury and lipid deposition.
  • Investigated the role of carnitine palmitoyl transferase 1B (CPT1B) in FA transport.
  • Evaluated the effects of L-carnitine (LC) intervention.

Main Results:

  • Uric acid (UA) induces cardiomyocyte injury and cytoplasmic lipid accumulation.
  • UA suppresses CPT1B, inhibiting mitochondrial FA transport.
  • LC treatment ameliorates UA-induced cardiac lipid deposition and LVR.
  • LC intervention reduced left ventricular anterior wall thickening in HUA mice.

Conclusions:

  • FA transport dysfunction is a key mechanism in HUA-induced cardiomyocytic injury and LVR.
  • Promoting FA transport via LC is a viable therapeutic strategy for HUA-associated LVR.
  • Targeting FA metabolism offers a novel approach to managing cardiovascular complications of HUA.

Keywords:
L-carnitinecardiomyocytesfatty acidhyperuricemiaventricular remodeling

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

245
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

707

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
22
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
21
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
728
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
15
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16